| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
2 companies
Robert C. Goeltz II is Chief Financial Officer at RCUS and has filed Form 4s across 2 companies. From May 2016 to May 2026, the filings on record show 1 open-market purchase and 11 sales. Robert C. Goeltz II's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.7M at current prices.
Historically, Robert C. Goeltz II's trades have earned a strong insider score of 72/100 across 12 rated trades. Over a 12-month horizon, 85.7% of those trades were profitable, with an average 12-month return of +11.6%.
The biggest single holding is RCUS (~$1.6M) as Chief Financial Officer. The RCUS filings lean toward selling, a net 45,183 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Sep 9, 2020 | RCUS Arcus Biosciences, Inc. | Chief Financial Officer | Buy | 5,000 | $21.57 | $107,848.50 | New | |
| Mar 20, 2017 | CTMX Cytomx Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 21,517 | $19.81 | $426,340.00 | -68.7% |